@article{Turco_F-2022_82897,
title = {What experts think about prostate cancer management during the COVID-19 pandemic: report from the Advanced Prostate Cancer Consensus Conference 2021},
author = {Turco, F. and Armstrong, A. and Attard, G. and Beer, T. and Beltran, H. and Bjartell, A. and Bossi, A. and Briganti, A. and Bristow, R. and Bulbul, M. and Caffo, O. and Chi, K. and Clarke, C. and Clarke, N. and Davis, I. and de Bono, J. and Duran, I. and Eeles, R. and Efstathiou, E. and Efstathiou, J. and Evans, C. and Fanti, S. and Feng, F. and Fizazi, K. and Frydenberg, M. and George, D. and Gleave, M. and Halabi, S. and Heinrich, D. and Higano, C. and Hofman, M. and Hussain, M. and James, N. and Jones, R. and Kanesvaran, R. and Khauli, R. and Klotz, L. and Leibowitz, R. and Logothetis, C. and Maluf, F. and Millman, R. and Morgans, A. and Morris, M. and Mottet, N. and Mrabti, H. and Murphy, D. and Murthy, V. and Oh, W. and Ekeke, O. and Ost, P. and O'Sullivan, J. and Padhani, A. and Parker, C. and Poon, D. and Pritchard, C. and Rabah, D. and Rathkopf, D. and Reiter, R. and Rubin, M. and Ryan, C. and Saad, F. and Sade, J. and Sartor, O. and Scher, H. and Shore, N. and Skoneczna, I. and Small, E. and Smith, M. and Soule, H. and Spratt, D. and Sternberg, C. and Suzuki, H. and Sweeney, C. and Sydes, M. and Taplin, M. and Tilki, D. and Tombal, B. and Türkeri, L. and Uemura, H. and Uemura, H. and van Oort, I. and Yamoah, K. and Ye, D. and Zapatero, A. and Gillessen, S. and Omlin, A.},
month = {feb},
year = {2022},
abstract = {Patients with advanced prostate cancer (APC) may be at greater risk for severe illness, hospitalisation, or death from coronavirus disease 2019 (COVID-19) due to male gender, older age, potential immunosuppressive treatments, or comorbidities. Thus, the optimal management of APC patients during the COVID-19 pandemic is complex. In October 2021, during the Advanced Prostate Cancer Consensus Conference (APCCC) 2021, the 73 voting members of the panel members discussed and voted on 13 questions on this topic that could help clinicians make treatment choices during the pandemic. There was a consensus for full COVID-19 vaccination and booster injection in APC patients. Furthermore, the voting results indicate that the expert's treatment recommendations are influenced by the vaccination status: the COVID-19 pandemic altered management of APC patients for 70% of the panellists before the vaccination was available but only for 25% of panellists for fully vaccinated patients. Most experts (71%) were less likely to use docetaxel and abiraterone in unvaccinated patients with metastatic hormone-sensitive prostate cancer. For fully vaccinated patients with high-risk localised prostate cancer, there was a consensus (77%) to follow the usual treatment schedule, whereas in unvaccinated patients, 55% of the panel members voted for deferring radiation therapy. Finally, there was a strong consensus for the use of telemedicine for monitoring APC patients.},
journal = { European Urology},
publisher = {Elsevier},
url = {http://dx.doi.org/10.1016/j.eururo.2022.02.010},
}
